Experience

BioIVT

• United States
• Biotechnology Research
• 200 - 300 Employee

• Technical Sales Specialist

  • Jun 2023 - Present



Greiner Bio-One North America, Inc.

• United States
• Medical Equipment Manufacturing
• 200 - 300 Employee

• National Key Account Manager for Pharma & Biotech

  • Feb 2022 - Jun 2023

  Establishes and develops corporate, long-term relationships withKey US-based Pharmaceutical accounts for Greiner Bio-One. Responsible for creating strategic account plans while using a consultative approach to oversee & coordinate customer interactions across all account sites. Additionally, I coordinate with internal GBO teams to identify solutions and provide value to our customers. Utilize my technical background to help local account managers to identify, qualify, and support opportunities. Show less

• Account Manager & Product Specialist - CO, AZ, UT, and NM

  • Jan 2015 - Apr 2022

  Greiner Bio-One is a German manufacturing company focused on providing state of the art plastic products to the healthcare industry for both hospitals and laboratories worldwide. As a BioScience Account Manager, I represent my company by building multi-level long term relationships with academic institutions, biotechnology companies, biopharma companies, healthcare professionals, and distributor representatives within assigned geography of CO, AZ, UT, NM and WY. In addition to my responsibilities as an account manager, I am also the Western Area 3D Technical Sales Specialist for Greiner Bio-One covering half of the US. In this position I am responsible for helping customers with their 3D biology questions including, but not limited to, on-boarding and protocol guidance, assay development and consultative protocol tweaks for assay optimization & troubleshooting, general education such as helping customers understand what 3D cell culture is and how it can help them obtain their research goals as well as how the magnetic 3D system works. Skilled presenter with extensive technical seminar experience including representation at national conferences. Show less

• Sales Account Manager & 3D Technical Specialist

  • Jan 2015 - Apr 2022



University of Colorado Denver

• United States
• Higher Education
• 700 & Above Employee

• Professional Research Associate

  • Jun 2012 - Jan 2015

  My previous research project involved working on understanding the unique relationship between human neurons and varicella zoster virus in a pure neuronal population in vitro. The goal was to establish a model of latent in vitro infection in order to study reactivation of the virus for shingles prevention research. Using immunocytochemistry, quantitative PCR, paired-end directional RNA sequence analysis, and western blot we investigate viral and cellular pathways influenced during lytic and non-lytic infections in vitro. Show less



University of Northern Colorado

• United States
• Higher Education
• 700 & Above Employee

• Microbiology Laboratory Preparation Manager and Teaching Assistant

  • Aug 2010 - Jun 2012

  Microbiology Laboratory Prep Manager:Prepared all materials required for the Microbiology course for sophomores at Univ. of N. Colorado. My duties involved culturing over twenty bacterial species and preparing all media types (over thirty) for continued culturing for over one hundred students per semester.Teaching Assistant for Introduction to Human Anatomy and Physiology from 2011-2012 and Biology 101 in the Fall of 2010. Developed syllabus, lectures, entry and exit quizzes, and all laboratory practical’s, graded all assignments and determined all lab grades. Show less

• Graduate Student and Student Researcher

  • Aug 2008 - Jun 2012

  Conducted preliminary research on orally administered malaria vaccines with Dr. Susan M. Keenan. Briefly, we identified three antigenic targets of Plasmodium (P.) falciparum, one antigenic target per lifecycle stage. Specifically, Sporozoite Surface Protein 2 (SSP2) from the liver stage, Merozoite Surface Protein 1-19 (MSP1-19) from the blood stage, and Plasmodium falciparum surface protein 48/45 (Pfs48/45) from the sexual stage of infection. Using standard cloning techniques we generated four plant expression vectors containing these antigenic targets of P. falciparum individually and combined. To show proof of concept and vector functionality, we genetically engineered Agrobacterium tumefaciens to contain the expression vector containing the liver stage antigenic sequence. Finally, utilizing the modified A. tumefaciens we transformed the model plant Arabidopsis thaliana and showed the expression of the liver stage antigen SSP2 through western blot analysis of the plant matter. To summarize, we demonstrated that A. thaliana derived SSP2 protein was recognized by human antibodies to P. falciparum SSP2 antigen. The project gave proof of concept that plants are capable of producing P. falciparum proteins that are recognized by human derived antibodies to P. falciparum, providing preliminary data for future malaria vaccine research. Show less



Colorado Center for Biorefining & Biofuels (C2B2)

• United States
• Research Services

• Research Internship

  • May 2009 - Aug 2009

  I investigated the role of the rice FtsH3 protease in biomass accumulation to guide future improvements of more intractable bioenergy crops under Dr. Jan Leach at Colorado State University. We silenced the FtsH3 protease in rice seeds using genetically engineered Agrobacterium tumefaciens and studied the phenotypic results as well as identify single nucleotide polymorphisms in FtsH3 using genomic sequencing techniques. I investigated the role of the rice FtsH3 protease in biomass accumulation to guide future improvements of more intractable bioenergy crops under Dr. Jan Leach at Colorado State University. We silenced the FtsH3 protease in rice seeds using genetically engineered Agrobacterium tumefaciens and studied the phenotypic results as well as identify single nucleotide polymorphisms in FtsH3 using genomic sequencing techniques.